Molecular simulations uncover a new druggable pocket in SARS-CoV-2’s spike protein which could hold the key to blocking COVID-19 infections.
A newly-designed antimicrobial polymer offers a 2-in-1 solution to combat multidrug-resistant bacteria.
The discovery of a new, highly conserved druggable site on the HIV reverse transcriptase could turn the tide in the wake of growing drug resistance.
When combined with low doses of antibiotics, this biodegradable polymer can reduce or even reverse antimicrobial resistance.
A new method of identifying drug targets in the malaria parasite P. falciparum could find broad applications in other fields of biology.
Could there be a drug that can both treat and protect against COVID-19? The answer may be found in antibody drugs, a promising therapeutic modality against the coronavirus.
Uttam Surana shares how SiNOPSEE Therapeutics, the biopharmaceutical startup he co-founded, is developing drugs to block angiogenesis in cancer and degenerative eye conditions.
Tipped off by artificial intelligence, a research team is testing whether a rheumatoid arthritis drug could be repurposed as a COVID-19 treatment.
Scientists are one step closer to developing effective treatments against Plasmodium vivax parasites, thanks to the ability to culture one of its closest cousins.
A*STAR scientists have developed a method to measure crucial protein-protein interactions in cancer cells, with implications for drug design and discovery.
A three-dimensional liver organoid model for studying dormant malaria parasites may pave the way for better antimalarial drugs.